Classify and define the signs of malignant hyperthermia
HYPERMETABOLISM
INCREASED SNS (PaCO2)
MUSCLE DAMAGE
HYPERTHERMIA
What is the inheritance pattern of malignant hyperthermia
Autosomal Dominant
What is the predominant abnormality in malignant hyperthermia sensitive individuals
Skeletal muscle receptor (ryanodine receptor: RYR-1)
Allows excessive accumulation of intracellular calcium in response to a triggering event –> skeletal muscle hypermetabolism
When do the symptoms of MH usually manifest?
Usually within 1 hour of induction
But anytime during administration of triggering agents
Very rarely postoperatively
What are the three early clinical indicators for the development of MH
Describe the common anaesthetic/surgical related problems that might mimic MH
1 .Insufficient anaesthesia/analgaesia (usually ↓PaCO2)
Apart from the common anaesthetic/surgical related problems which might mimic MH, what are other disease conditions included in the DDx
What is the immediate treatment approach for MH
Supportive ABCDEFGHIJKLMNOP A - site ETT B - Hyperventilate FiO2 1 C - Large bore D - Dantrolene mixing people E - Cool patient
Specific
HYPERMETABOLISM
- 2.5 mg/kg IV BOLUS (180 mg in 70kg adult)
- Need to dilute 9 bottles 20 mg each with 60mL Sterile and preservative free water
= 540 milliliters
- Monitor etCO2/HR for response
- May need up to 10 mg/kg (36 bottles)
HYPERKALAEMIA
ACIDOSIS
- NaHCO3: 1 - 2 mEq/kg IV push over 5 - 10 mins
No CCB (use amiodarone)
What is the mortality of MH subsequent to the availability of Dantrolene
1 - 17%